Pharmaceuticals & Therapeutics

A key FDA alignment for zervimesine not only de-risks a pivotal trial but signals a new era for treating the devastating psychosis of an overlooked dementia.

An alliance of biopharma innovators is set to discuss a critical hurdle in medicine: delivering RNA therapies to tissues beyond the liver, a key to unlocking new treatments.

BOTOX® Cosmetic is investing millions in women entrepreneurs. Is it smart philanthropy, or a brilliant new blueprint for brand building and corporate strategy?

A new report shows AI directs 80% of aesthetic medicine searches to AbbVie & Galderma, creating a 'visibility gap' that leaves 11,500 small clinics invisible.

With a $2.74M grant from The Michael J. Fox Foundation, biotech startup X-tosis is advancing a novel therapy that aims to fix the cell's failing powerhouses.

With a key grant from Breakthrough T1D, MannKind aims its inhaled insulin at children. Is this a life-changing innovation or a high-stakes corporate revival?

Quoin Pharma's new drug name is a key step, but the path to the first-ever treatment for a rare skin disease reveals the complex interplay of innovation and finance.

A novel drug aims to reverse myelin damage in MS, a feat no current therapy can achieve. But with a recent FDA hold, is Quantum BioPharma's vision a breakthrough or a mirage?

BioMendics secured a key FDA Fast Track designation for its EBS therapy, a strategic move that de-risks development and signals a new era for rare disease treatment.

With a novel nasal spray targeting the host, not the virus, RA Capital-backed NorthLinks Bio aims to create a broad-spectrum defense against respiratory threats.

Right Brain Bio is leveraging Dassault Systèmes' powerful MEDIDATA platform to accelerate a radical new therapy that could reverse Parkinson's pathology.

Zevra Therapeutics' new data for MIPLYFFA in infants with NPC is more than a medical update; it's a key commercial milestone to widen its market.

In a head-to-head battle, Takeda's zasocitinib showed superior skin clearance over a key competitor, signaling a potential new standard for oral therapy.

A new partnership between AGEPHA Pharma and Close-Up Intl reveals how AI is not just a buzzword, but a critical tool for getting vital medicines to patients.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

An FDA fast-track for a devastating brain disease drug is a beacon of hope for patients and a major validation of Alphabet's long-term biotech strategy.

A new, fast-acting neurotoxin with a two-week lifespan just hit the market. Allergan's Boey® aims to capture hesitant consumers with a low-commitment 'trial run'.

Insmed recruits J&J and Novartis veteran Samuele Butera to execute the multi-billion-dollar launch of BRINSUPRI and expand its respiratory franchise.

A new survey reveals the crippling cost of insulin, forcing millions to choose between medicine and groceries. A bipartisan bill may offer a lifeline.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?